KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Working Capital Changes: 2011-2024

Historic Other Working Capital Changes for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$16.9 million.

  • Esperion Therapeutics' Other Working Capital Changes rose 138.82% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 435.87%. This contributed to the annual value of -$16.9 million for FY2024, which is 177.11% down from last year.
  • Esperion Therapeutics' Other Working Capital Changes amounted to -$16.9 million in FY2024, which was down 177.11% from $21.9 million recorded in FY2023.
  • Esperion Therapeutics' Other Working Capital Changes' 5-year high stood at $21.9 million during FY2023, with a 5-year trough of -$16.9 million in FY2024.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$2.8 million (2022), whereas its average is $733,667.
  • As far as peak fluctuations go, Esperion Therapeutics' Other Working Capital Changes soared by 879.18% in 2023, and later crashed by 177.11% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Other Working Capital Changes (Yearly) stood at $2.4 million in 2020, then soared by 93.56% to $4.7 million in 2021, then tumbled by 160.37% to -$2.8 million in 2022, then soared by 879.18% to $21.9 million in 2023, then plummeted by 177.11% to -$16.9 million in 2024.